<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82326">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02033590</url>
  </required_header>
  <id_info>
    <org_study_id>SURE-005</org_study_id>
    <nct_id>NCT02033590</nct_id>
  </id_info>
  <brief_title>Clinical and Economic Outcomes With the Use of SERI® Surgical Scaffold in Direct-to-implant Breast Reconstruction</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <brief_summary>
    <textblock>
      The objective of this study is to prospectively observe clinical and economic outcomes with
      the use of SERI® in direct-to-implant breast reconstruction.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Incidence rate of implant loss (SERI® and breast implant)</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Reconstruction</condition>
  <arm_group>
    <arm_group_label>SERI® Surgical Scaffold</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biodegradable (purified) surgical silk scaffold</intervention_name>
    <arm_group_label>SERI® Surgical Scaffold</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be willing to undergo immediate breast reconstruction following a skin-sparing or
             nipple sparing mastectomy with healthy, sufficiently thick, well-vascularized skin
             flaps, and the implantation of SERI® Surgical Scaffold and breast implant

          -  Be female, between 18 and 65 years of age at the time of enrollment

        Exclusion Criteria:

          -  Have undergone prior radiation treatment on the study breast(s) and/or is
             preoperatively evaluated to require radiation treatment to the study breast(s) during
             the course of the study

          -  Have undergone a skin reducing mastectomy

          -  Have a BMI that is &lt;17 or ≥ 30

          -  Predicted implant weight more than 500 grams

          -  Have a known allergy to silk

          -  Have an abscess or active infection at any location within one month prior to surgery

          -  Be pregnant, lactating, or if of childbearing potential, be unwilling to use
             contraceptive methods and avoid pregnancy throughout the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>October 8, 2014</lastchanged_date>
  <firstreceived_date>January 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
